Key indicators: single-crystal X-ray study; T = 113 K; mean (C-C) = 0.002 Å; R factor = 0.030; wR factor = 0.079; data-to-parameter ratio = 18.2.
In the title compound, C 13 H 16 N 4 OS 3 , a thienopyridinederivative, the tetrahydropyridine ring exhibits a half-chair conformation, and the folded conformation of the molecule is defined by the N-C-C-N torsion angle of À78. 85 (16) . The crystal packing features intermolecular C-HÁ Á ÁN, N-HÁ Á ÁN and C-HÁ Á ÁO hydrogen bonds.
Related literature
The title compound is a potential antiplatelet agent. As irreversible P2Y12 antagonists, thienopyridines have proved the relevance of inhibiting signaling via the platelet-specific P2Y12 ADP receptor in the prevention of cardiovascular events, see: Iyengar (2009); Franchini & Mannucci, (2009); Van Giezen et al. (2009); Van Giezen & Humphries (2005) . For a related structure, see : Chen et al. (2010) . For the synthesis of the title compound, see: Liu et al. (2008) .
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). 3, 5, 6, 
Comment
As irreversible P2Y12 antagonists, the thienopyridines (e.g., clopidogrel and prasugrel) have been further proved the relevance of inhibiting signaling via the platelet-specific P2Y12 ADP receptor in the prevention of cardiovascular events (Iyengar, 2009; Van Giezen & Humphries, 2005; Franchini, et al., 2009) . The structure of the title compound (I), a new derivative of thienopyridine, is presented here.
The tetrahydropyridine ring is in a half-chair conformation ( 
Refinement
The N-H bond was restrained to 0.90 Å, and other H atoms were positioned geometrioncally and refined using a riding model, with d(C-H)=0.95-0.99 Å, and U iso (H)=1.2U eq (C) of the parent atom. Figures   Fig. 1 . The molecular structure of (I), with the atom-numbering scheme and 50% probability displacement ellipsoids. 3, 5, 6, 
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